🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis

RecruitingNAAges 15 Years - 35 YearsAllCentre Hospitalier Universitaire de Saint Etienne
NCT05813457 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia. Numerous studies show that the rapidity of the initial management of FPE would reduce the risk of negative evolution and would have a decisive impact on the short and long term prognosis. The rapidity of this management can be measured by the duration of untreated psychosis, or DUP (Duration of Untreated Psychosis), the time interval between the appearance of the first frank psychotic symptoms and the initiation of adequate psychiatric care. The objective of this study is to show the impact of an intervention facilitating access to specialized care for PEP on the reduction of DUP. This intervention consists of an early identification program for FPE, the PRESTO program, specifically targeting

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or brief psychotic disorder established according to DMS 5 * Never having taken neuroleptic treatment for antipsychotic purposes, except for the current episode and for a duration of \< 6 month * Oral consent of the patient or, for minors, of his/her parents to participate in the study Exclusion Criteria: * Patients already treated and followed for FPE * Brief psychotic state not requiring specific management
💊

What it tests

  • PRESTO Early Identification Program
📍

Where

6 sites
Hospices Civils de Lyon
Bron, France
Chu Clermont-Ferrand
Clermont-Ferrand, France
Chu Grenoble
Grenoble, France
CHU de Montpellier
Montpellier, France
CHU de Nîmes
Nîmes, France
Chu Saint Etienne
Saint-Etienne, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy